Microvast Holdings announces departure of chief financial officer
In a recent filing with the Securities and Exchange Commission, BioLife Solutions Inc. (NASDAQ:BLFS) reported that Todd Berard, the company’s Chief Marketing Officer, sold 424 shares of common stock. The transaction, which took place on March 3, 2025, was executed at a price of $25.46 per share, resulting in a total sale value of approximately $10,795. The stock, which currently trades at $26.25, has shown significant momentum with a 46% gain over the past year. According to InvestingPro analysis, the company appears to be trading above its Fair Value.
Following this transaction, Berard holds 106,538 shares of BioLife Solutions. InvestingPro data reveals the company maintains strong liquidity with a current ratio of 4.54, while operating with a moderate debt level. The sale was conducted under a Rule 10b5-1 trading plan, which Berard had adopted to satisfy tax withholding obligations related to the vesting of restricted stock. For deeper insights into BLFS’s financial health and additional ProTips, check out the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, BioLife Solutions reported strong fourth-quarter financial results, surpassing expectations with revenues of $22.7 million, slightly above the projected $22.0 million. The company also posted a narrower-than-expected loss of $0.04 per share, compared to analyst estimates of a $0.08 loss. The Cell Processing segment was a significant contributor, with a 37% year-over-year revenue increase to $20.3 million, marking its fifth consecutive quarter of growth. Benchmark maintained its Buy rating on BioLife Solutions with a $30 target, citing the strong earnings and optimistic financial outlook as key factors. Looking ahead, BioLife Solutions anticipates 2025 revenue growth between 16% and 20%, with expectations to reach $95.5 million to $99 million, exceeding the analyst consensus of $95.45 million. The company also forecasts Cell Processing revenue to grow 18-21% to $86.5-$89 million. Additionally, BioLife Solutions highlighted the integration of its biopreservation media in 17 approved cell and gene therapies, with more approvals expected in the next 12 months. These developments emphasize BioLife Solutions’ strategic focus on its high-margin core business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.